Las Vegas, NV -- (SBWIRE) -- 12/03/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Biostar Pharmaceuticals Inc (NASDAQ:BSPM), James River Coal Company (NASDAQ:JRCC), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) managed to keep its gain at 8.72% on above-normal volume of 2.03M shares. The stock settled at $1.87 after floating in a range of $1.71 to $1.93. Its latest price has reached market capitalization of $101.23 million. Its 52-week range has been $0.41 to $3.65. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development.
Has CPRX Found The Bottom and Ready To Move Up? Find Out Here
Biostar Pharmaceuticals Inc (NASDAQ:BSPM) traded up on a volume of 2.04 million, higher than its standard daily volume. Shares have gained 38.12% to $2.50. Over the last twelve months, the stock has gained 155.1% and faced a worst price of $0.62. Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its wholly owned subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar) and its variable interest entity (VIE) Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical), develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the People’s Republic of China.
For How Long BSPM’s Gloss will Attract Investors? Find out via this report
James River Coal Company (NASDAQ:JRCC) settled 13.99% higher at $1.63 on above-normal volume of 1.81M shares during the last trading day. The stock has its 12-month high at $3.97 and 52-week low price was $1.15. It traded in a range of $1.41 to $1.71 during the last trading day. James River Coal Company mines engaged in processing and selling of thermal and metallurgical coal through eight active mining complexes located throughout eastern Kentucky, southern West Virginia and southern Indiana. The Company has two business segments based on the coal basins in which it operates: Central Appalachia (CAPP) and the Midwest.
Why Should Investors Buy JRCC After the Recent Fall? Just Go Here and Find Out
In the last trading session, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) was down on high volume, trading at a volume of 1.77M versus its average daily volume of 1.39 million shares. At $3.24, the stock has attained market capitalization of 184.99 million. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Why Should Investors Buy IMUC After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)